Legal Representation
Attorney
Sydney R. Jensen
USPTO Deadlines
Next Deadline
64 days remaining
Non-Final Action Mailed
Due Date
October 07, 2025
Extension Available
Until January 07, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
6 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 7, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 7, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jul 7, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jun 27, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jan 17, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jan 17, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicines; drugs; pharmaceuticals; pharmaceutical preparations; therapeutics; therapeutic pharmaceuticals; therapeutic agents; cell therapies; biopharmaceuticals; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; drugs for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cells for medical or clinical purposes; viral or non-viral delivery vectors for medical or clinical purposes; proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; targeted cell therapies; cell therapy products; gene therapy products; therapeutic antigens and antibodies; engineered cells; bioengineered cells; cell engineering platforms; protein design platforms; computational protein design platforms; AI-powered protein design platforms; pharmaceutical preparations developed with a computational protein design platform; pharmaceutical preparations developed with AI-powered protein design platforms; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;
Classification
International Classes
005